David Charytan, MD
Enriched profileNorman S. Wikler Professor of Medicine and Director, Division of Nephrology, NYU Grossman School of Medicine / NYU Langone Health · NYU Langone Health
David Charytan is Norman S. Wikler Professor of Medicine and Director, Division of Nephrology, NYU Grossman School of Medicine / NYU Langone Health at NYU Langone Health. OpenAlex indexes 309 publications with 22,973 citations (h-index 59); ClinicalTrials.gov lists 7 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 5% of Nephrology profiles in the findmyKOL directory.
Data verified 14 Aug 2026
Overview
Updated 15 Oct 2026
David Charytan, MD, is Norman S. Wikler Professor of Medicine and Director, Division of Nephrology, NYU Grossman School of Medicine / NYU Langone Health. The public record shows 309 publications with 22,973 citations (h-index 59), centered on Dialysis and Renal Disease Management, Chronic Kidney Disease and Diabetes, Diabetes Treatment and Management. It also documents an investigator role on 7 registered clinical trials, industry payments reported by 13 companies, 5 NIH-funded awards (2019–2026).
- Top research focus: Dialysis and Renal Disease Management
- 7 registered trials on ClinicalTrials.gov
- Open Payments reporting from 13 companies
Generated from the cited public record · current as of 15 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 43 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 147.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 15 Oct 2026
Listed as an investigator on 7 registered studies on ClinicalTrials.gov. The most recent:
- Transcutaneous Auricular Vagus Nerve Stimulation Device in CKD Population
Sponsor: NYU Langone Health
- Safety and Efficacy of Empagliflozin in Hemodialysis
Sponsor: NYU Langone Health
- Potassium Containing Salt-Substitute in Hemodialysis-Dependent End Stage Kidney Disease
Sponsor: NYU Langone Health
Industry payments
Updated 15 Oct 2026
13 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Fresenius USA Marketing, Inc.Program year20254 payments
- AstraZeneca ABProgram year20251 payment
- CSL BehringProgram year20252 payments
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
50.3%Angiotensin receptor blocker (ARB)13.8%Losartan Potassium100%Part D≥13 patientsNonsteroidal Mineralocorticoid-Receptor Antagonist8%Kerendia100%Part D<11 patients+ 5 more classes in this area
Metabolism & gastrointestinal
45.8%SGLT2 inhibitor28.5%Farxiga81%Jardiance19%Part D<11 patientsVitamin D3 Analog11.9%Calcitriol100%Part D<11 patients+ 1 more class in this area
Other
3.8%Drugs for treatment of hyperkalemia and hyperphosphatemia3.8%Lokelma100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 15 Oct 2026
5 NIH research awards on record, funded 2019–2026 per NIH RePORTER. The latest:
- Deep learning on ECGs to improve outcomes in patients on dialysis
Icahn School of Medicine at Mount Sinai
FY2026$679,999R01HL167050 - Intradialytic Myocardial Stunning in Hemodialysis Patients - a Novel Cardiovascular Risk Factor
New York University School of Medicine
FY2026$670,338R01HL157220 - Deep learning on ECGs to improve outcomes in patients on dialysis
Icahn School of Medicine at Mount Sinai
FY2025$730,082R01HL167050
Congress activity
Updated 15 Oct 2026
4 congress contributions (2020–2023) across ADA per OpenAlex. The most recent:
- 125-OR: Disparities in Access to Sodium–Glucose Cotransporter-2 Inhibitors (SGLT2i)
ADA Scientific Sessions
ADA2023Co-authorOral - 1130-P: Mediators of the Effects of Canagliflozin (CANA) on Heart Failure (HF) and CV Death in Patients with Type 2 Diabetes (T2D) and Chronic Kidney Disease (CKD)
ADA Scientific Sessions
ADA2020Co-authorPoster - 26-OR: Acute Declines in EGFR during Treatment with Canagliflozin and Its Implications for Clinical Practice: Insights from CREDENCE
ADA Scientific Sessions
ADA2020Co-authorOral
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Extracorporeal membrane oxygenation in patients with severe respiratory failure from COVID-19
Intensive Care Medicine
2021
Most-cited works
by citation count (OpenAlex)- 01Canagliflozin and Renal Outcomes in Type 2 Diabetes and NephropathyArticle6,051 citations2019
- 02BMP-7 counteracts TGF-β1–induced epithelial-to-mesenchymal transition and reverses chronic renal injuryArticle1,343 citations2003
- 03Factors Associated With Death in Critically Ill Patients With Coronavirus Disease 2019 in the USArticle1,043 citations2020
- 04
- 05
Network
Updated 15 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 15 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- LinkedIn
linkedin.com/in/david-charytan-15477118
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com ↗ - ResearchGate
researchgate.net/profile/David-Charytan
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net ↗ - Doximity
doximity.com/pub/david-charytan-md
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →doximity.com ↗
Mentions by others
where others cite or feature them- Other
kidney.org/press-room/nkf-to-honor-nephrologist-and-nyu-professor-medicine-dr-david-charytan-distinguished-j
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →kidney.org ↗ - YouTube
youtube.com/watch
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com ↗ - X / Twitter
X (Twitter) account @DCharytan associated with David Charytan, nephrology/kidney disease content
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →x.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 15 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →nyulangone.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →nyulangone.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →nyulangone.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →nyulangone.org ↗
- MSc in Epidemiology
Harvard School of Public Health
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →kidney.org ↗
Editorial & leadership roles
journal and society appointments- Director
Division of Nephrology, NYU Langone Health / NYU Grossman School of Medicine
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →nyulangone.org ↗ - Associate Editor
Clinical Journal of the American Society of Nephrology (CJASN)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →kidney.org ↗ - Founding Steering Committee member
NIH Hemodialysis Novel Therapies Consortium
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →kidney.org ↗
Awards & honors
honors on the public record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →kidney.org ↗
Media & interviews
press, podcasts and appearances- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →radcliffecardiology.com ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →asn-online.org ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Gareth Morgan, MD
NYU Langone Health
Nathan Levin, MD
NYU Langone Health
Ira Jacobson, MD
NYU Langone Health
Michael Zelefsky, MD
NYU Langone Health
Howard Scher, MD
Memorial Sloan Kettering Cancer Center
Toni Choueiri, MD
Dana-Farber Cancer Institute
Robert Motzer, MD
Memorial Sloan Kettering Cancer Center
Fred Saad, MD
Centre hospitalier de l'Université de Montréal (CHUM)